Oncocross

382150· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩3,310+9.42%

2026-08-04

Financials

Valuation Metrics

Oncocross's Market Cap is ₩432B. At end of 2025 it was ₩1250B. Ranked #1827 of 2,436 in KR market (top 75%), #1121 of 1,649 on KOSDAQ (top 68%), #200 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 85%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	43.18B KRW	KR#1,827/2,436 Sec#200/234
Revenue	475.2M KRW	KR#2,396/2,436 Sec#223/234
Net Income	-9.31B KRW	KR—/2,436 Sec—/234
Total Assets	34.63B KRW	KR#2,299/2,436 Sec#214/234
Net Assets	11.70B KRW	KR#2,353/2,436 Sec#224/234
Employees	31	KR#2,175/2,436 Sec#201/234
Value
P/B	3.69x	KR#2,177/2,436 Sec#176/234
P/S	90.88x	KR#2,386/2,436 Sec#208/234
Profitability
ROE	-79.55%	KR#2,323/2,436 Sec#215/234
ROA	-26.88%	KR#2,273/2,436 Sec#189/234
Op. Margin	-1884.98%	KR#2,396/2,436 Sec#222/234
Revenue Growth	167.31%	KR#76/2,436 Sec#13/234
Financial Health
Debt Ratio	295.96%	KR#2,126/2,436 Sec#220/234
Total Debt	8.16B KRW	KR#1,679/2,436 Sec#156/234
Cash	1.45B KRW	KR#2,298/2,436 Sec#220/234
Current Ratio	3.75x	KR#459/2,436 Sec#75/234
Performance
1Y Return	-65.34%	KR#2,308/2,436 Sec#219/234
1M Return	-13.24%	KR#1,940/2,436 Sec#193/234
From 52W High	-77.16%	KR#2,316/2,436 Sec#216/234
1Y MDD	-80.64%	KR#2,307/2,436 Sec#215/234
Trading
Volume	42,794 shares	KR#1,440/2,436 Sec#142/234
Foreign Own.	0.62%	KR—/2,436 Sec—/234
Per Share
EPS	-774 KRW	KR—/2,436 Sec—/234
BPS	959 KRW	KR#2,290/2,436 Sec#207/234

Company Info

CEO 김이랑, 강지훈 (각자대표)

Employees 31

Founded 2015

HQ 서울특별시 송파구, KR

Website www.oncocross.com/

동사는 2015년 설립되어 2024년 코스닥시장에 기술성장기업으로 상장한 중소·벤처기업임. AI 기반 신약개발 플랫폼 RAPTOR AI, ONCO-RAPTOR AI, ONCOfind AI를 개발하여 적응증 발굴, 병용약물 스크리닝, 치료 타겟 탐색 서비스를 제공함. 전통적 신약개발의 장기 소요와 높은 실패율 문제를 AI 기반 전사체 데이터 분석으로 해결하여 임상 성공 확률을 높이고 R&D 생산성을 개선하는 혁신을 추구하고 있음. 온코크로스는 2015년에 설립되었으며 서울특별시 송파구에 본사를 두고 있습니다.